Eam Investors, LLC Supernus Pharmaceuticals, Inc. Transaction History

Eam Investors, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$31.09 - $37.88 $963,914 - $1.17 Million	31,004 Added 88.52%	66,030 $2.36 Million
Q3 2022 Nov 14, 2022	BUY	$28.79 - $35.41 $1.01 Million - $1.24 Million	35,026 New	35,026 $1.19 Million
Q3 2018 Nov 08, 2018	SELL	$42.7 - $56.55 $2.3 Million - $3.05 Million	-53,910 Closed	0 $0
Q2 2018 Aug 03, 2018	BUY	$44.1 - $59.85 $2.38 Million - $3.23 Million	53,910 New	53,910 $3.23 Million
Q4 2017 Feb 12, 2018	SELL	$36.4 - $42.6 $2.15 Million - $2.51 Million	-58,967 Closed	0 $0
Q3 2017 Nov 08, 2017	BUY	$36.75 - $49.65 $2.17 Million - $2.93 Million	58,967	58,967 $2.36 Million

282

60.9M

27.7K

11.3K

Ticker SUPN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 53,495,300
Market Cap $1.93B
Description
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...

Get notified when there are updates to the investment portfolio of Eam Investors, LLC, based on Form 13F filings with the SEC.

Stay updated on Eam Investors, LLC with notifications on news.